153 related articles for article (PubMed ID: 29914752)
1. Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study.
Caputo D; Cartillone M; Cascone C; Pozzi D; Digiacomo L; Palchetti S; Caracciolo G; Coppola R
Pancreatology; 2018 Sep; 18(6):661-665. PubMed ID: 29914752
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-enabled blood tests for early detection of pancreatic ductal adenocarcinoma.
Caputo D; Caracciolo G
Cancer Lett; 2020 Feb; 470():191-196. PubMed ID: 31783084
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
[TBL] [Abstract][Full Text] [Related]
4. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
6. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.
Liu X; Fu Y; Chen Q; Wu J; Gao W; Jiang K; Miao Y; Wei J
BMC Gastroenterol; 2018 Nov; 18(1):168. PubMed ID: 30400836
[TBL] [Abstract][Full Text] [Related]
7. Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis.
Chen YT; Huang ZP; Zhou ZW; He MM
Med Oncol; 2016 Nov; 33(11):122. PubMed ID: 27730526
[TBL] [Abstract][Full Text] [Related]
8. Circulating IL-35 in pancreatic ductal adenocarcinoma patients.
Jin P; Ren H; Sun W; Xin W; Zhang H; Hao J
Hum Immunol; 2014 Jan; 75(1):29-33. PubMed ID: 24121041
[TBL] [Abstract][Full Text] [Related]
9. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
10. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection.
Caputo D; Quagliarini E; Coppola A; La Vaccara V; Marmiroli B; Sartori B; Caracciolo G; Pozzi D
Int J Surg; 2023 Oct; 109(10):2934-2940. PubMed ID: 37352522
[TBL] [Abstract][Full Text] [Related]
12. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
13. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
14. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma.
Schlitter AM; Jesinghaus M; Jäger C; Konukiewitz B; Muckenhuber A; Demir IE; Bahra M; Denkert C; Friess H; Kloeppel G; Ceyhan GO; Weichert W
Eur J Cancer; 2017 Oct; 84():121-129. PubMed ID: 28802189
[TBL] [Abstract][Full Text] [Related]
15. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
16. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.
Sharma A; Smyrk TC; Levy MJ; Topazian MA; Chari ST
Gastroenterology; 2018 Aug; 155(2):490-500.e2. PubMed ID: 29723506
[TBL] [Abstract][Full Text] [Related]
17. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma.
Karabicak I; Satoi S; Yanagimoto H; Yamamoto T; Hirooka S; Yamaki S; Kosaka H; Inoue K; Matsui Y; Kon M
J Hepatobiliary Pancreat Sci; 2016 Dec; 23(12):750-755. PubMed ID: 27794194
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma.
Waragai Y; Suzuki R; Takagi T; Sugimoto M; Asama H; Watanabe K; Kikuchi H; Hikichi T; Masamune A; Kang Y; Fleming JB; Ohira H
Pancreatology; 2016; 16(6):1044-1050. PubMed ID: 27665173
[TBL] [Abstract][Full Text] [Related]
20. Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis.
Meng Z; Cao M; Zhang Y; Liu Z; Wu S; Wu H
BMC Gastroenterol; 2019 Apr; 19(1):59. PubMed ID: 31014264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
